Description:
This randomized phase II trial studies how well giving busulfan, cyclophosphamide, and
melphalan or busulfan and fludarabine phosphate before donor hematopoietic cell transplant
works in treating younger patients with juvenile myelomonocytic leukemia. Giving chemotherapy
before a donor hematopoietic transplant helps stop the growth of cancer cells. It may also
stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem
cells from a donor are infused into the patient, they may help the patient's bone marrow make
stem cells, red blood cells, white blood cells, and platelets. It is not yet known whether
giving busulfan, cyclophosphamide, and melphalan or busulfan and fludarabine phosphate before
a donor stem cell transplant is more effective in treating juvenile myelomonocytic leukemia.
<span class="go-doc-concept go-doc-intervention">Busulfan</span>, <span class="go-doc-concept go-doc-intervention">Cyclophosphamide</span>, and <span class="go-doc-concept go-doc-intervention">Melphalan</span> or <span class="go-doc-concept go-doc-intervention">Busulfan and Fludarabine</span> Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia
Title
Brief Title: Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia
Official Title: A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children With Juvenile Myelomonocytic Leukemia (JMML)
Clinical Trial IDs
NCT ID: NCT01824693
ORG ID: ASCT1221
NCI ID: NCI-2013-00738
Trial Conditions
Juvenile Myelomonocytic Leukemia
Trial Interventions
Drug |
Synonyms |
Arms |
busulfan |
BSF, BU, Misulfan, Mitosan, Myeloleukon |
Arm I (busulfan, cyclophosphamide, melphalan), Arm II (busulfan, fludarabine phosphate) |
cyclophosphamide |
CPM, CTX, Cytoxan, Endoxan, Endoxana |
Arm I (busulfan, cyclophosphamide, melphalan) |
melphalan |
Alkeran, CB-3025, L-PAM, L-phenylalanine mustard, L-Sarcolysin |
Arm I (busulfan, cyclophosphamide, melphalan) |
fludarabine phosphate |
2-F-ara-AMP, Beneflur, Fludara |
Arm II (busulfan, fludarabine phosphate) |
tacrolimus |
FK 506, Prograf |
Arm I (busulfan, cyclophosphamide, melphalan), Arm II (busulfan, fludarabine phosphate) |
mycophenolate mofetil |
Cellcept, MMF |
Arm I (busulfan, cyclophosphamide, melphalan), Arm II (busulfan, fludarabine phosphate) |
Trial Purpose
This randomized phase II trial studies how well giving busulfan, cyclophosphamide, and
melphalan or busulfan and fludarabine phosphate before donor hematopoietic cell transplant
works in treating younger patients with juvenile myelomonocytic leukemia. Giving
chemotherapy before a donor hematopoietic transplant helps stop the growth of cancer cells.
It may also stop the patient's immune system from rejecting the donor's stem cells. When the
healthy stem cells from a donor are infused into the patient, they may help the patient's
bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not
yet known whether giving busulfan, cyclophosphamide, and melphalan or busulfan and
fludarabine phosphate before a donor stem cell transplant is more effective in treating
juvenile myelomonocytic leukemia.
Detailed Description
PRIMARY OBJECTIVES:
I. To compare - in a randomized fashion - the day 100 treatment related mortality (TRM)
incidence for two myeloablative conditioning regimens, busulfan-fludarabine (fludarabine
phosphate) (BU-FLU) and busulfan-cyclophosphamide-melphalan (BU-CY-MEL), prior to
hematopoietic cell transplant (HCT) for children with juvenile myelomonocytic leukemia
(JMML), in order to determine the preferred regimen for future trials.
II. To compare - in a randomized fashion - the 18-month event-free survival (EFS) following
two different myeloablative conditioning regimens (BU-FLU vs. BU-CY-MEL) prior to HCT for
children with JMML, in order to determine the preferred regimen for future trials.
SECONDARY OBJECTIVES:
I. To determine the 18-month relapse incidence (RI) following two different myeloablative
conditioning regimens (BU-FLU vs. BU-CY-MEL) prior to HCT for children with JMML.
II. To determine the graft failure rates following two different myeloablative conditioning
regimens (BU-FLU vs. BU-CY-MEL) prior to HCT for children with JMML.
TERTIARY OBJECTIVES:
I. To determine the rates of severe toxicities (grade 3/4) at day 100 post-HCT between the
two myeloablative conditioning regimens (BU-FLU vs. BU-CY-MEL).
II. To determine the rates of acute and chronic (at 18 months post-HCT) graft-versus-host
disease (GVHD) following HCT using two different conditioning regimens (BU-FLU vs.
BU-CY-MEL) in children with JMML.
III. To create a JMML-specific pre-HCT index to allow better risk-stratification of future
patients.
IV. To determine the feasibility of assessing post-transplant disease burden by donor
chimerism measurements and allele-specific polymerase chain reaction (PCR) in mononuclear
and sorted cell subsets.
V. To validate gene expression and methylation classifiers predictive of relapse in patients
with JMML.
VI. To comprehensively assess genetic and biochemical alterations amongst patients with JMML
who are treated on this transplant protocol.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I:
CONDITIONING REGIMEN: Patients receive busulfan intravenously (IV) over 2-3 hours once daily
(QD), every 12 hours, or every 6 hours on days -8 to -5, cyclophosphamide IV over 60 minutes
QD on days -4 and -3, and melphalan IV over 15-30 minutes on day -1.
TRANSPLANT: Patients undergo allogeneic HCT on day 0.
Patients receive tacrolimus IV or orally (PO) on days -1 to 98 (related donor) or 180
(unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30
(related donor) or 45 (unrelated donor).
ARM II:
CONDITIONING REGIMEN: Patients receive busulfan as in Arm I and fludarabine phosphate IV
over 30-60 minutes on days -5 to -2.
TRANSPLANT: Patients undergo allogeneic HCT as in Arm I.
Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated
donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related
donor) or 45 (unrelated donor).
After completion of study treatment, patients are followed up for 5 years.
Trial Arms
Name |
Type |
Description |
Interventions |
Arm I (busulfan, cyclophosphamide, melphalan) |
Experimental |
CONDITIONING REGIMEN: Patients receive busulfan IV QD, every 12 hours, or every 6 hours over 2-3 hours on days -8 to -5, cyclophosphamide IV QD over 60 minutes on days -4 and -3, and melphalan IV over 15-30 minutes on day -1.
TRANSPLANT: Patients undergo allogeneic HCT no sooner than 24 hours after the last dose of chemotherapy.
Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor). |
busulfan, cyclophosphamide, melphalan, tacrolimus, mycophenolate mofetil |
Arm II (busulfan, fludarabine phosphate) |
Experimental |
CONDITIONING REGIMEN: Patients receive busulfan as in Arm I and fludarabine phosphate IV over 1 hour on days -5 to -2.
TRANSPLANT: Patients undergo allogeneic HCT as in Arm I.
Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor). |
busulfan, fludarabine phosphate, tacrolimus, mycophenolate mofetil |
Eligibility Criteria
Inclusion Criteria:
- Patients must have a strong clinical suspicion of JMML, based on a modified category
1 of the revised diagnostic criteria; specifically, eligible patients must have all
of the following:
- Splenomegaly
- Absolute monocyte count (AMC) > 1000/uL
- Blasts in peripheral blood (PB)/bone marrow (BM) < 20%
- For the 7-10% of patients without splenomegaly, the diagnostic entry criteria must
include all other features described above and at least 2 of the following criteria:
- Circulating myeloid precursors
- White blood cell (WBC) > 10,000/uL
- Increased fetal hemoglobin (HgbF) for age
- Sargramostim (GM-CSF) hypersensitivity OR, patients must have been previously
diagnosed with JMML
- Patients must be previously untreated with HCT
- All patients and/or their parents or legal guardians must sign a written informed
consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute
(NCI) requirements for human studies must be met
Exclusion Criteria:
- Patients with a known germline mutation of PTPN11 (Noonan's Syndrome) are not
eligible
- Patients with a known history of NF1 (Neurofibromatosis Type 1) and either
- A history of a tumor of the central nervous system (astrocytoma or optic
glioma), or
- A malignant peripheral nerve sheath tumor with a complete remission of < 1 year
are not eligible
- Human immunodeficiency virus (HIV) positive patients are not eligible
Minimum Eligible Age: 3 Months
Maximum Eligible Age: 18 Years
Eligible Gender: Both
Primary Outcome Measures
Treatment-related mortality (TRM)
EFS
Secondary Outcome Measures
Relapse/non-response rates
Graft failure rates
Trial Keywords